Financial Performance - The company's operating revenue for the first half of 2023 reached ¥3,186,169,198.27, representing an increase of 18.66% compared to ¥2,685,211,897.14 in the same period last year[20]. - Net profit attributable to shareholders of the listed company was ¥131,378,322.44, a significant increase of 91.31% from ¥68,673,476.49 in the previous year[20]. - The net cash flow from operating activities surged to ¥385,321,534.68, a remarkable increase of 2,276.33% compared to ¥16,214,972.69 in the same period last year[20]. - Basic earnings per share increased to ¥0.15, up 87.50% from ¥0.08 in the same period last year[22]. - The company reported a net profit of ¥78,656,255.61 after deducting non-recurring gains and losses, which is an increase of 114.31% from ¥36,702,741.91 in the previous year[20]. - The diluted earnings per share increased to ¥0.14, reflecting a growth of 75.00% from ¥0.08 in the same period last year[22]. - The company's total liabilities decreased to CNY 3,572,855,512.40 from CNY 4,017,232,033.86, a reduction of approximately 11.06%[117]. - The company reported a total comprehensive income of CNY 131,925,645.43 for the first half of 2023, up from CNY 69,208,626.19 in the same period last year, an increase of 90.9%[121]. Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥8,337,385,997.95, a decrease of 4.47% from ¥8,727,665,447.53 at the end of the previous year[21]. - The company's total liabilities as of June 30, 2023, were CNY 2,500,000,000, indicating a stable financial position compared to the previous reporting period[111]. - The total current assets as of June 30, 2023, amounted to CNY 3,202,459,212.95, a decrease from CNY 3,508,825,519.23 at the end of 2022, reflecting a decline of approximately 8.7%[111]. - The total equity of the company rose to CNY 2,856,972,616.22, compared to CNY 2,795,583,940.96 in the previous year, marking an increase of 2.2%[117]. Research and Development - Research and development expenses for the first half of 2023 amounted to CNY 146,959,987.51, an increase of 12.3% compared to CNY 130,755,765.74 in the same period last year[120]. - The company is focusing on a large formulation strategy to enhance the competitiveness of core products, leading to rapid growth in sales data for these products[28]. - The company plans to enhance its product pipeline, focusing on the development of anti-infection drugs, diabetes medications, and cardiovascular products[42]. Market and Sales - The company reported a significant sales breakthrough with new products generating revenue of CNY 135 million in the first half of the year[28]. - The revenue from human drug formulations increased by 34.43% year-on-year, with five newly launched products contributing 11.81% to the total formulation revenue[40]. - The veterinary drug segment saw a revenue increase of 53%, amounting to 234 million yuan, effectively stabilizing income and profit in this sector[41]. - The company plans to enhance its market expansion strategies and invest in new product development in the upcoming quarters[111]. Environmental and Social Responsibility - The company is recognized as a national "green factory" and is actively pursuing clean production and low-carbon development strategies[38]. - The company has established self-monitoring plans in accordance with pollution discharge permits, and all monitoring results have been uploaded to the Shandong Provincial Pollution Source Monitoring Information Sharing System, with all indicators meeting national requirements in the first half of the year[74]. - The company invested CNY 5.3685 million in energy-saving technologies, resulting in a total coal savings of 2,376.8 tons and a CO2 reduction of 6,179.68 tons during the first half of 2023[85]. - The company participated in the "Four Advances" initiative, sending 6 management personnel to assist in local poverty alleviation and rural revitalization efforts, receiving high recognition from local governments[86]. Financial Management - The company has reduced financial expenses by 52.18%, from ¥30,323,432.12 to ¥14,501,900.89, due to adjustments in loan structure and a decrease in interest rates[54]. - The company has increased its long-term borrowings by 58.65%, from ¥867,176,000.00 to ¥1,372,276,000.00, as part of its loan restructuring strategy[55]. - The company raised CNY 1,062,000,000.00 through borrowings in the first half of 2023, compared to CNY 573,971,072.49 in the same period last year, indicating an increase of 85.2%[128]. Risks and Challenges - The company faces risks from policy changes, particularly in the pharmaceutical industry, which could impact its operations and profitability[61]. - The company is exposed to risks from significant fluctuations in raw material prices, which could affect its profit margins[62]. - The company emphasizes the importance of R&D, investing heavily to mitigate risks associated with long development cycles and market alignment[64].

证券代码：600789 证券简称：鲁抗医药 公告编号：2023-036 山东鲁抗医药股份有限公司 第十届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东鲁抗医药股份有限公司（以下简称"公司"）十届董事会第十九 次会议于 2023 年 8 月 18 日上午9:00 在公司高新园区1310 会议室以现场结 合通讯方式召开。本次会议召开的通知已于 2023 年 8 月 8 日以电子邮件方 式发出。会议应参会董事9 人，实际参与表决 9 人。会议由董事长彭欣先生 主持，本次会议的召开符合《公司法》和《公司章程》的规定，形成的决 议合法、有效。经过认真讨论，审议并通过了如下决议： 一、《2023 年半年度报告及摘要》 同意 9 票，反对 0 票、弃权 0 票 二、《关于解聘公司副总经理的议案》 同意 9 票，反对 0 票、弃权 0 票 因职务变动，会议同意解聘王爱煜先生担任的副总经理职务，自本次会议审 议通过之日起执行。 公司独立董事对上述事项发表独立意见如下：公司董事会审议解聘王爱煜先 生担任的副 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2023—035 山东鲁抗医药股份有限公司 关于头孢克肟片通过仿制药一致性评价的公告 规格： 0.1g、50mg（按 C16H15N5O7S2 计） 批准文号：国药准字 H20040656、国药准字 H20060879 药品标准：YBH11862023 注册分类：化学药品 生产企业：山东鲁抗医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）收到国家药品监督管 理局颁发的关于头孢克肟片（以下简称"该药品"）的《药品补充申请批准通知书》 （通知书编号：2023B03979，2023B03980），该药品通过仿制药质量和疗效一 致性评价。现将相关情况公告如下： 一、药品证书基本信息 药品名称： 头孢克肟片 剂型： 片剂 2023 年 8 月 18 日 审批结论：通过仿制药质量和疗效一致性评价。 二、药品研发及市场情况 头孢克肟为第三代口服头孢菌素类抗生素，通过阻止细菌细胞壁的合成发挥 杀菌作用，其对某些 β- ...

证券代码:600789 股票简称:鲁抗医药 公告编号:临 2023-034 山东鲁抗医药股份有限公司 关于两全资子公司吸收合并完成工商登记变更的公告 法定代表人：曹海峰 注册资本：25588 万元 住 所：山东省济宁市邹城市邹城工业园区华鲁路 50 号 经营范围：许可项目：兽药生产；兽药经营；食品添加剂生产；饲料添加剂 生产【分支机构经营】；饲料生产【分支机构经营】。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准） 一般项目：技术进出口；货物进出口；饲料添加剂销售；食品添加剂销售； 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；专用化学产 品销售（不含危险化学品）；化工产品销售（不含许可类化工产品）；生物化工 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于 2022 年 12 月 28 日召 开了十届董事会第十六次（临时）会议，审议通过了《关于全资子公司吸收合并 的议案》，同意全资子公司山东鲁抗舍里乐药 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2023-021 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 山东鲁抗医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 11 日(星期四)至 05 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lkpc_dmc@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 山东鲁抗医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 19 日发 布公司 2022 年度报告和 2023 年第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,669,812,908.04, representing a year-on-year increase of 25.42% compared to CNY 1,324,581,073.87 in the same period last year[3]. - The net profit attributable to shareholders of the listed company was CNY 45,688,589.04, a slight increase of 1.59% from CNY 44,588,853.42 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 77.02% to CNY 41,375,154.29 from CNY 23,629,646.82 in the same period last year[3]. - The company reported a basic earnings per share of CNY 0.05, unchanged from the previous year[4]. - The total comprehensive income for the first quarter of 2023 was CNY 47,414,780.36, an increase from CNY 46,090,528.29 in the same period of 2022, representing a growth of approximately 2.86%[16]. Cash Flow - The net cash flow from operating activities increased by 92.05% to CNY 130,889,329.27, compared to CNY 68,459,009.16 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was CNY 130,889,329.27, significantly higher than CNY 68,153,420.75 in Q1 2022, indicating an increase of about 92.4%[18]. - The total cash inflow from financing activities was CNY 697,270,082.10 in Q1 2023, compared to CNY 228,329,538.31 in Q1 2022, reflecting a substantial increase of approximately 205.5%[19]. - The net cash flow from financing activities for Q1 2023 was -CNY 137,996,819.86, worsening from -CNY 9,018,694.18 in Q1 2022[19]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 323,314,673.48, down from CNY 395,130,807.40 at the end of Q1 2022, a decrease of about 18.2%[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,548,945,159.23, a decrease of 2.50% from CNY 8,727,665,447.53 at the end of the previous year[4]. - Current liabilities decreased to ¥3,526,689,113.33 from ¥4,129,057,002.94, representing a reduction of 14.6%[12]. - The total liabilities decreased to ¥4,979,764,208.53 from ¥5,220,496,898.35, a decline of 4.6%[13]. - Long-term borrowings increased to ¥1,236,885,323.06 from ¥867,176,000.00, indicating a rise of 42.5%[12]. Shareholder Information - The company has 116,523 common shareholders as of the end of the reporting period[8]. - The top shareholder, Hualu Holdings Group Co., Ltd., holds 20.91% of the shares, totaling 185,896,620 shares[8]. Research and Development - Research and development expenses increased to ¥72,066,772.99 in Q1 2023, compared to ¥60,176,722.79 in Q1 2022, marking a rise of 19.7%[15]. Inventory and Expenses - Inventory as of March 31, 2023, was ¥1,503,632,882.92, slightly up from ¥1,480,685,151.67 at the end of 2022[12]. - The cash paid for purchasing goods and services in Q1 2023 was CNY 635,306,475.83, down from CNY 741,247,430.29 in Q1 2022, representing a decrease of about 14.3%[18]. - The company received CNY 18,184,609.68 in tax refunds during Q1 2023, compared to CNY 23,881,168.78 in Q1 2022, a decline of approximately 23.9%[18]. - The company incurred cash outflows of CNY 73,776,345.22 for taxes in Q1 2023, which is significantly higher than CNY 27,151,145.58 in Q1 2022, an increase of about 171.5%[18]. Acquisition - The company acquired a 60% stake in Shandong Rukang Zhonghe Environmental Technology Co., Ltd. for CNY 62.0659 million, which was completed on August 24, 2022, and is now a wholly-owned subsidiary[4].

Financial Performance - In 2022, the company achieved a consolidated net profit attributable to shareholders of the parent company of CNY 138,013,129.39, representing a 54.90% increase compared to the previous year[6]. - The operating revenue for 2022 was CNY 5,621,441,903.66, which is a 14.17% increase from CNY 4,923,783,870.87 in 2021[22]. - The net cash flow from operating activities reached CNY 444,377,008.97, marking a significant increase of 150.36% compared to CNY 177,492,024.62 in the previous year[22]. - The total assets of the company at the end of 2022 were CNY 8,727,665,447.53, an increase of 11.57% from CNY 7,822,429,397.11 at the end of 2021[23]. - The net assets attributable to shareholders of the parent company were CNY 3,356,856,234.48, reflecting a 2.25% increase from CNY 3,282,963,859.81 in 2021[23]. - Basic earnings per share increased by 60% to CNY 0.16 in 2022 from CNY 0.10 in 2021[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 86,962,978.51, which is a 141.76% increase from CNY 35,971,269.00 in the previous year[22]. - The gross profit from the main business reached 1.22 billion RMB, an increase of 5.68% compared to the previous year[50]. - The total revenue for 2022 was approximately CNY 5.54 billion, with a gross profit margin of 22.01%, reflecting a year-over-year decrease of 1.67 percentage points[59]. Strategic Developments - The company plans to distribute a cash dividend of CNY 0.55 per 10 shares (including tax) to all shareholders[6]. - The company’s future plans and strategic developments are subject to investment risks and do not constitute a commitment to investors[7]. - The company plans to continue expanding its product pipeline and enhancing marketing capabilities to drive future growth[59]. - The company aims to maintain and improve market share in niche products through flexible sales strategies and optimized business lines[86]. - The company will actively conduct industry policy research to align with policy directions and enhance brand building[86]. - The company is committed to promoting transformation and upgrading through consistent evaluation and new product development[87]. - The company plans to enhance research and development efforts, focusing on anti-infection products and expanding its product pipeline across multiple therapeutic areas[87]. Research and Development - R&D investment for 2022 was CNY 311 million, with significant progress in the pipeline for anti-infection and cardiovascular drugs[35]. - The company holds 47 new patent authorizations in 2022, enhancing its technological and innovation capabilities[51]. - The company has developed a complete product chain from fermentation raw materials to semi-synthetic raw materials and formulations, covering over 500 specifications[44]. - The company is focusing on innovative drugs and generic drug applications, biotechnology product development, and product transformation to enhance its product portfolio[106]. - The total R&D investment for the reporting period was CNY 311 million, accounting for 5.52% of total operating revenue, which is relatively high compared to industry peers[106]. - The company is actively expanding its product types and strengthening its product chain through scientific research and development efforts[106]. Market Performance - Revenue from formulation products reached CNY 1.902 billion in 2022, with new product sales contributing over CNY 70 million[33]. - The revenue from the antibiotic segment was CNY 255.82 million, with a gross profit margin of 18.53%, showing a year-over-year decrease of 10.46%[59]. - The revenue from veterinary antibiotics increased significantly, reaching CNY 2.31 billion, with a gross profit margin of 15.66%, marking a year-over-year increase of 43.04%[59]. - The domestic revenue accounted for CNY 4.78 billion, with a gross profit margin of 23.96%, reflecting a year-over-year increase of 16.09%[59]. - The company is recognized as one of the four major antibiotic production bases in China, with a strong market presence in penicillin and cephalosporin products[52]. Operational Efficiency - The company achieved a cost reduction of CNY 78.7827 million through efficiency improvements and production optimization[34]. - The company invested CNY 157 million in production automation, establishing 12 post-packaging production lines and deploying 14 robots, resulting in a 45.77% increase in labor productivity[37]. - The company’s automation and information technology initiatives have been recognized as a national pilot demonstration project by the Ministry of Industry and Information Technology[36]. - The company has implemented a dynamic management system for suppliers, ensuring quality and reducing procurement costs[45]. Environmental Responsibility - The company’s environmental investment in 2022 was CNY 173.39 million, with successful completion of pollution control assessments for three subsidiaries[38]. - The company is committed to enhancing its environmental and safety standards in response to increasing regulatory pressures, aiming for compliance with national carbon neutrality goals[135]. - The company has established a governance structure to protect the interests of shareholders, particularly minority shareholders, ensuring transparent information disclosure[191]. - The company was recognized as a national-level "Green Factory," reflecting its commitment to environmental responsibility and sustainable practices[188]. Governance and Compliance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal requirements and facilitating shareholder participation[138]. - The board of directors operates under strict regulations, with established committees to enhance decision-making and oversight functions[139]. - The company adheres to strict information disclosure regulations, preventing selective disclosure and insider trading[141]. - The company has a comprehensive risk management report that was approved in the last board meeting of the year[156]. Future Outlook - The company aims for a revenue target of 6 billion yuan in 2023, representing a year-on-year growth of over 7%[124]. - Financial guidance for the upcoming fiscal year suggests a projected revenue growth of approximately 15%[148]. - The company plans to enhance the profitability and competitiveness of its raw materials through the "Peak Plan" and aims to optimize technology and quality while reducing costs[125]. - The company is positioned to benefit from the stable implementation of volume-based procurement policies, seeking innovation and channel expansion to enhance profitability[121].

Group 1: Event Details - The event is organized by Shandong Securities Regulatory Bureau and Shandong Listed Companies Association [1] - The online event will take place on November 16, 2022, from 14:00 to 16:00 [1] - Investors can participate via the "Investor Relations Interactive Platform" provided by P5W [1] Group 2: Company Representatives - The company's Chairman, Mr. Peng Xin, will be present for the online communication [1] - The Chief Financial Officer, Mr. Li Li, will also participate in the event [1] - Other representatives include Board Secretary Mr. Tian Lixin and Securities Affairs Representative Mr. Bao Qiangming [1] Group 3: Discussion Topics - Topics for discussion include corporate governance and social responsibility/ESG [1] - The company's operational status and development strategy will be addressed [1] - Risk prevention and investor protection, along with the third-quarter report, will be key points of interest [1]

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600789 证券简称：鲁抗医药 山东鲁抗医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|------------------|------------------------------|------------------|---------------------------- ...

2022 年半年度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2022 年半年度报告 1 / 149 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）荣姝伟声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别 ...